Slide 1: Enabling the Nervous System to Repair Itself
Enabling the Nervous System to Repair Itself Corporate Presentation June 2024
Slide 2: Financial Disclosure Statement
Financial Disclosure Statement Not an offer or solicitation: This document is provided for general information purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security in any jurisdiction. The contents of this document have not been approved or disappr
Slide 3: NervGen Highlights
NervGen Highlights NVG-291, a novel first-in-class drug candidate with potential to repair nervous system damage and restore motor, sensory and cognitive function Demonstrated functional improvement in six different preclinical models in several independent labs Phase 1b/2a in spinal cord injury und
Slide 4: Leadership
Leadership Mike Kelly, MBA Bill Adams, CPA, CA Dan Mikol, MD, PhD Chuck Olson, DSc Liz Eberhardt, BSc, magna Matvey Lukashev, PhD Chief Executive Officer Chief Financial Officer Chief Medical Officer Sr. VP, Technical Operations cum laude VP, Research & Preclinical Mike has over 30 years of Bill has
Slide 5: History of NervGen Technology
History of NervGen Technology 1990s 2009 2015 2018 2023 Dr. Silver discovered Dr. Silver and collaborators Dr. Silver's team designed a NervGen licensed NVG- NervGen has initiated a that glial scars contains from Harvard co- peptide (NVG-291-R) 291 global rights for Phase 1b/2a placebo- chondroitin
Slide 6: NVG-291: Product Candidate Overview
NVG-291: Product Candidate Overview • Cell-penetrating peptide, 35 amino acids in length • Designed to cross cell membranes for enhanced cellular uptake of the drug • Route of administration is subcutaneous injection • Manufactured by chemical synthesis • Discovery focused on analogs with new compos
Slide 7: Product Pipeline
Product Pipeline Multiple development opportunities CANDIDATE PROGRAM DISCOVERY PRECLINICAL PHASE 1 PHASE 1b/2a Spinal Cord Injury NVG-291 Stroke Amyotrophic Lateral Sclerosis Stroke Amyotrophic Lateral Sclerosis NVG-300* Alzheimer's Disease Multiple Sclerosis Next-Generation Candidate Selection Com
Slide 8: Nervous System Damage Has Limited Treatment Alternatives
Nervous System Damage Has Limited Treatment Alternatives Glial scars and accumulation of CSPGs suppress CNS repair Key Repair Mechanisms Injury Plasticity glial scar Formation of new neuronal connections and rewiring of existing ones Injury Brain Axonal Regeneration The ability of a severed axon to
Slide 9: Novel Therapy Under Development to Repair Nervous System Damage
Novel Therapy Under Development to Repair Nervous System Damage NVG-291 targets negative effects of CSPGs on CNS repair Key Repair Mechanisms Injury Plasticity glial scar Formation of new neuronal connections and rewiring of existing ones Injury Brain Axonal Regeneration NVG-291 The ability of a sev
Slide 10: Multiple Preclinical Studies Using NVG-291-R Report Improved CNS/PNS Repair
Multiple Preclinical Studies Using NVG-291-R* Report Improved CNS/PNS Repair Enhanced Plasticity, Repair (Axonal, Myelination), and Recovery of Function ACUTE SPINAL CHRONIC SPINAL STROKE MULTIPLE PERIPHERAL NERVE OPTIC NERVE CORD INJURY CORD INJURY (Ischemic, Hemorrhagic) SCLEROSIS (EAE) INJURY DEM
Slide 11: Nervous System Damage Markets and Opportunity
Nervous System Damage Markets and Opportunity Significant medical costs and morbidity SCI Ischemic Stroke ALS MS AD Incidence* 18,000 ~690,000 ~7,000 10,000 500,000 Prevalence* 291,000 9.4M ~25K-30K ~1M 6.7M Lifetime Cost* $1M-$4M+ $140,000+ $1.4M $4M+ $400,000 System Cost* $50B+ $57B $250M-$1.0B $8
Slide 12: SCI Demographics
SCI Demographics • Average age: ~43 • Male (78%), female (22%) • Cause: vehicle (38%); fall (33%); violence (15%); sports (8%) • Annual hospitalization (30%): UTI, pneumonia, decubitus ulcer • Duration of hospitalization and rehabilitation: 2 to 3 months • Chance of depression: 25% • Significant uri
Slide 13: SCI Facts and Figures
SCI Facts and Figures Incidence and Prevalence Economic Impact Individuals with SCI face a difficult and expensive journey through the healthcare system; that ~18,000 Spinal cord injuries every year in the US1 journey begins with 2-3 months in rehabilitation and costs $200,000 or more per patient3 P
Slide 14: Acute SCI Preclinical Study
Acute SCI Preclinical Study Basso, Beattie, Bresnahan Rating Scale Overview 20 21 = Normal • T8 compression injury Treatment Period function **** **** • 500 µg/day x 7 weeks **** 15 **** • Treatment began 1 day post injury NVG-291-R ≥14 = fine motor movements (N=10) Results 10 Occasional coordinatio
Slide 15: NVG-291-R: Severe Spinal Cord Injury Model
NVG-291-R: Severe Spinal Cord Injury Model Representative of Placebo Group Representative of NVG-291-R Group (Back Legs and Tail Dragging) (Back Legs and Tail Active) Play with solid fill Click here to play video Click here to play video Remarkable and robust repair across multiple models 15 Rink et
Slide 16: NVG-291-R: Severe Spinal Cord Injury Model
NVG-291-R: Severe Spinal Cord Injury Model Representative of Placebo Group Representative of NVG-291 Group Play with solid fill Click here to play video Click here to play video Hind legs are immobile Significant motor recovery: consistent coordination, toe clearance, tail held high consistently 16
Slide 17: Chronic SCI Preclinical Study
Chronic SCI Preclinical Study 20 Overview Treatment Period • C2 lateral hemisection Treatment period → 15 • 500 µg/day x 8.5 weeks *** *** ** • Treatment began 12 weeks post-injury * Forelimb Locomotor 10 NVG-291-R Rating Scale (N=8) Results Placebo • Significant recovery of forelimb locomotor (N=
Slide 18: Spinal Cord Injury
Spinal Cord Injury Bladder function improved following NVG-291-R treatment in preclinical animal studies 1.5 Bladder Dose Response1 ** * 1.0 Responders Void (2x SD of vehicle mean) 100% of animals in the Frequency (voids / hour) two highest dose groups had improved bladder 0.5 control function 1Anim
Slide 19: NVG-291 Phase 1 Clinical Trial Results
NVG-291 Phase 1 Clinical Trial Results Study Design Safety Results Single Dose • Well tolerated across all doses • 37 subjects − Maximum tolerated dose (MTD) not reached • 6 dose levels • No treatment discontinuations • Assessed through Day 8 • No serious/severe adverse events (AE) in NVG-291 Multip
Slide 20: Phase 1b/2a Proof-of-Concept Trial in SCI
Phase 1b/2a Proof-of-Concept Trial in SCI Study Design Study Objectives • 16-week trial (12-wk treatment, 4-wk noninterventional period) Co-Primary Endpoints: Quantitative Measure of Motor • Randomized 1:1 to NVG-291 and placebo Connectivity • Once daily subcutaneous injection • Hand muscle group •
Slide 21: SCI Clinical Advisory Board
SCI Clinical Advisory Board James Guest, MD, PhD, FACS Professor of Neurological Surgery at the University of Miami and The Miami Project to Cure Professor and Chair of the Department of Physical Medicine and Rehabilitation at Rutgers New Steven Kirshblum, MD Jersey Medical School Chief Medical Offi
Slide 22: Board of Directors
Board of Directors Glenn Ives Randall Kaye, MD Adam Rogers, MD Chairman CMO, Longboard Pharmaceuticals Former CEO & Co-Founder, Hemera Former Partner, Deloitte LLP Harold Punnett, DMD Mike Kelly John Ruffolo Co-Founder President & CEO, NervGen Founder & Managing Partner, Maverix Brian Bayley Krista
Slide 23: Share and Capital Structure
Share and Capital Structure Exchange/Market: Ticker TSX: NGEN.V OTCQB: NGENF Recent Share Price CA $2.00 US $1.46 (June 7, 2024) Shares Outstanding 70.0 million 92.1 million Fully Diluted (~12.0million options & retention securities, ~10.1 million warrants*) Insider Ownership 23.2% Cash & Cash Equiv
Slide 24: Key Value Drivers for 2024
Key Value Drivers for 2024 Phase 1b/2a clinical trial recruitment progress Preclinical data in multiple indications Next generation compound progress Phase 1b/2a Proof-of-concept readout in chronic SCI 24
Slide 25: Enabling the Nervous System to Repair Itself
Enabling the Nervous System to Repair Itself www.nervgen.com Certain images in this presentation are sourced from Flaticon All trademarks are the property of their respective Company owners